Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 108Triple Negative Breast Neoplasms 27Neoplasm Metastasis 17Sarcoma 16Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Brain Neoplasms 5Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Carcinoma, Transitional Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Recurrence 2Pancreatic Neoplasms 2Melanoma 2Lymphoma 2Lung Neoplasms 2Leiomyosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma 2Advanced Breast Cancer 2

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × eribulin × Clear all
NCT03237780 2026-05-13

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT04579224 2026-05-13

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
184 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01126749 2022-02-28

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Eisai Inc.

Phase 1/2 Terminated
92 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡